Loading clinical trials...
Loading clinical trials...
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of the Fixed-Dose Combination (FDC) of Obeticholic Acid (OCA) and Bezafibrate (BZF) tablet in Subjects with Primary Biliary Cholan...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Intercept Pharmaceuticals
NCT07304843 · Primary Biliary Cholangitis (PBC)
NCT07449793 · Primary Biliary Cholangitis (PBC), Primary Biliary Cholangitis
NCT05751967 · Primary Biliary Cholangitis
NCT05749822 · Primary Biliary Cholangitis
NCT06755541 · Primary Biliary Cholangitis (PBC)
University of Alabama at Birmingham
Birmingham, Alabama
Southern California Research Center
Coronado, California
Tampa General Medical Group
Tampa, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions